|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fabio Gratton, CEO of inVibe, discusses patient-focused drug development (PFDD), his company’s language model, and the value this technology brings to a patient’s treatment journey.
|
|
|
Antoine Al-Achi, PhD, Mounika Nangineedi, MS, Chaitali Koli, MS, et al, study 19 drugs with varying partition coefficient, water solubility, and molecular weight values to compare their diffusion through the middle epithelial membrane of onion with that of their Caco-2 cell line.
|
|
|
Bill Vincent believes if the industry wants to keep moving up the steep growth curve, then capacity and raw materials must be readily available. The innovations in therapies, platforms, and processes will all come with time, money, and increasing availability of resources.
|
|
|
In part 1 of this 3-part series, PharmaCircle, in collaboration with Drug Development & Delivery, focuses on a global review of 2021 product approvals.
|
|
|
|
|
|
|
|
|

Eurofins BioPharma Product Testing offers complete CMC Testing Services for the Bio/Pharmaceutical industry, including all starting materials, process intermediates, drug substances, drug product, packaging, and manufacturing support through our broad technical expertise in Biochemistry, Molecular & Cell Biology, Virology, Chemistry and Microbiology. With a global capacity of more than 2,000,000 square feet of facilities and 37 locations worldwide, our network of GMP laboratories and vast experience allow us to support projects of any size from conception to market. Our local presence with four key sites in the US, including Lancaster, PA; Portage, MI; Columbia, MO; and San Diego, CA, ensures personal service backed by a unique global breadth of harmonized capabilities that supports all functional areas of bio/pharmaceutical drug development. Click here for more.

Video Spotlight: Lonza (Small Molecules)

|
|
|
|
|
|
 |
|
Particle Works’ game-changing particle engineering platforms are set to revolutionize the way customers discover, develop and scale-up particle production for a wide range of….
|
|
 |
|
Catalent recently announced a multi-year $350-million investment at its facility in Bloomington, IN, to expand biologics drug substance and drug product manufacturing….
|
|
 |
|
Brooklyn ImmunoTherapeutics, Inc. recently announced the establishment of a new corporate and research and development facility at The Boardwalk at Science Center Drive in San Diego, CA, to support translational….
|
|
 |
|
ProMed Pharma recently announce the initiation of preclinical evaluation of a novel fully resorbable contraceptive implant. The implant, developed in a project funded by the Bill & Melinda….
|
|
 |
|
Cocrystal Pharma, Inc. recently announced a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for exploratory preclinical studies to….
|
|
|
|
|
|
|
|
 |
|
Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications…..
|
|
 |
|
This webinar will explore how to conduct effective extractables and leachables (E&L) testing on plastic process materials used during pharmaceutical and biopharmaceutical manufacturing…..
|
|
|
|
|
|
|
|
 |
|
The demand for complex, often life-saving drug substances such as monoclonal antibodies, interferons, and peptides is on the rise, creating a greater need for innovative delivery mechanisms to administer these new therapeutics. For a variety of reasons, sub-visible particles can …
|
|
 |
|
Absorption of molecules from the gastrointestinal tract is an essential consideration when developing orally delivered medications. Solubility, the concentration of drug in solution, is essential for this to occur and it is important to also consider the dissolution rate of …
|
|
 |
|
ABSTRACT
Lipid nanoparticles (LNPs) are powerful carriers for the delivery of biotherapeutics and active pharmaceutical ingredients (APIs). They are attractive due to their size and biocompatibility, which are important factors when determining the efficacy of an encapsulated API. Particle Works’ …
|
|
|
|
|
Upcoming eNewsletter Features:
May 4 – Transdermal/Topical Delivery
May 11 – Particle Design Technology
|
|
|
|
|
|
|
|